Insulin secretagogues: Who, what, when, and how?

被引：2

作者：

Dailey G. ^{[1
]}

机构：

[1] Scripps Clinic, La Jolla, CA 92037

来源：

Current Diabetes Reports | 2005年 / 5卷 / 5期

关键词：

Hypoglycemia; Sulfonylurea; Glibenclamide; Insulin Glargine; Repaglinide;

D O I：

10.1007/s11892-005-0089-x

中图分类号：

学科分类号：

摘要：

Sulfonylurea compounds were the first available oral antidiabetic agents and they remain an important tool in our quest for optimal glycemic control. The more recent introduction of meglitinides offers an approach to short-term insulin release with minimal hypoglycemic risk during fasting periods. Published trials suggest that individuals with a hemoglobin A1c above 8.5% are unlikely to reach currently recommended targets (6.5% to 7%) without the use of one of these insulin secretagogues. Starting and probable maximally effective doses for glimepiride are 1 to 2 mg initially and 4 mg thereafter. For glyburide and glipizide, these are 2.5 to 5 mg initially, and 10 mg effective at a maximum. The large majority of the effect can be seen within a week, making them very attractive when rapid lowering of glucose is needed. An understanding of the principles will facilitate more effective use of initial and combination therapy. Copyright © 2005 by Current Science Inc.

引用

页码：329 / 332

页数：3

共 22 条

[1]

Henquin J., The fiftieth anniversary of hypoglycemic sulphonamides. How did the mother compound work?, Diabetologia, 35, pp. 907-912, (1992)

[2]

Dornhorst A., Insulinotropic meglitinide analogues, Lancet, 358, pp. 1709-1716, (2001)

[3]

Carroll M.F., Gutierrez A., Castro M., Et al., Targeting postprandial hyperglycemia: A comparitive study of insulinotropic agents in type 2 diabetes, J. Clin. Endocrinol. Metab., 88, pp. 5248-5254, (2003)

[4]

Esposito K., Guigliano D., Nappo F., Marfella R., Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus, Circulation, 110, pp. 214-219, (2004)

[5]

Simonson D.C., Kourides I., Feinglos M., Fischette C., Efficacy, safety, and dose-response of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM, Diabetes Care, 20, pp. 597-606, (1997)

[6]

Stenman S., Melander A., Groop P.H., Groop L., What is the benefit of increasing the sulfonylurea dose?, Ann. Intern. Med., 118, pp. 169-173, (1993)

[7]

Riddle M., Combining sulfonylureas and other oral agents, Am. J. Med., 108, (2000)

[8]

Fonseca V., Rosenstock J., Patwardhan R., Et al., Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: Randomized controlled trial, JAMA, 283, pp. 1695-1702, (2000)

[9]

Rendell M., The role of sulphonylureas in the management of type 2 diabetes mellitus, Drugs, 64, pp. 1339-1358, (2004)

[10]

American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management - 2002 Update, Endocr. Pract., 8, SUPPL. 1, pp. 41-82, (2002)

← 1 2 3 →